Bax and Bcl-X-L expression are not related to prognosis in patients with advanced esophageal squamous cell carcinoma
Citation
S. Natsugoe et al., Bax and Bcl-X-L expression are not related to prognosis in patients with advanced esophageal squamous cell carcinoma, CANCER LETT, 174(1), 2001, pp. 91-97
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
CANCER LETTERS
SICI code
0304-3835(200112)174:1<91:BABEAN>2.0.ZU;2-U
Abstract
Bax and Bcl-X-L genes play an important role in the apoptotic pathway. Thes
e expressions were immunohistochemically investigated in 111 patients with
advanced esophageal squamous cell carcinoma. The positive rates of p53, Bax
, and Bcl-XL were 42.3, 38.7, and 46.8%, respectively. The expression of bo
th Bax and Bcl-XL was not related to clinicopathological findings, includin
g survival. Neither Bax nor Bcl-XL expression correlated with p53 overexpre
ssion. Five-year survival rate did not differ according to the co-expressio
n pattern of Bax and Bcl-XL. In 44 patients who underwent chemotherapy and/
or radiation therapy after surgery, Bax and Bcl-XL expression was not relat
ed to patients' survival. Multiple apoptotic pathways may be associated wit
h advanced esophageal squamous cell carcinoma. (C) 2001 Elsevier Science Ir
eland Ltd. All rights reserved.